CEFOTAXIME (Claforan) 1 gramm/vial, 1 vial/pack

CEFOTAXIME (Claforan) - is an antibiotic used to treat a number of bacterial infections. Specifically it is used to treat joint infections, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis, gonorrhea, and cellulitis. It is given either by injection into a vein or muscle. Cefotaxime was discovered in 1976 and came into commercial use in 1980. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

USES

• Central Nervous System Infections (Meningitis).
• Infections of the Respiratory Tract and Nose, Ears, Throat.
• Urinary Tract Infections.
• Bones and Joints Infections.
• Skin and Soft Tissues Infections.
• Pelvic and Abdominal infections.
• Peritonitis, Sepsis, Endocarditis.
• Gonorrhea
• Infected Wounds and Burns.
• Salmonella.
• Lyme disease.
• Prevention of Infections After Surgery.
• As well as the following: Staphylococcus: spp and aureus Staphylococcus epidermidis Streptococcus: pneumoniae, pyogenes, agalactiae Enterococcus species Enterobacter spp Escherichia coli Haemophilus influenzae Haemophilus parainfluenzae Klebssiella: spp and pneumoniae Morganella morganii Neisseria gonorrhoeae Acinetobacter species Corynebacterium diphtheriae Erysipelothrix insidiosa Eubacterium spp Propionibacterium spp Bacillus subtilis Clostridium: spp and Clostridium perfringens Escherichia coli Citrobacter spp Proteus: mirabilis, indole, vulgaris Providencia: spp and Providencia rettgeri Serratia spp Pseudomonas aeruginosa Neisseria meningitidis Bacteroides: spp and Bacteroides fragilis Fusobacterium: spp andFusobacterium nucleatum Peptococcus spp Peptostreptococcus spp.

GUARANTEE & EXPIRY DATE

Original from Russian Kraspharma. Manufacturer may vary.

All packs are air tight sealed and expire up to 05.2027.

Photo of the product is for illustation purpose only and may vary.

DESCRIPTION

Historically, Cefotaxime has been considered to be comparable to ceftriaxone (another third-generation cephalosporin) in safety and efficacy for the treatment of bacterial meningitis, lower respiratory tract infections, skin and soft tissue infections, genitourinary tract infections, and bloodstream infections, as well as prophylaxis for abdominal surgery. The majority of these infections are caused by organisms traditionally sensitive to both cephalosporins. However, ceftriaxone has the advantage of once-daily dosing, whereas the shorter half-life of cefotaxime necessitates two or three daily doses for efficacy. Changing patterns in microbial resistance suggest cefotaxime may be suffering greater resistance than ceftriaxone, whereas the two were previously considered comparable. Considering regional microbial sensitivities is also important when choosing any antimicrobial agent for the treatment of infection.

PACKAGING

CEFOTAXIME comes in the form powder for dilution with Water for Injection or Lidocaine for IV or IM administration:

1000 mg per vial. One vial per pack.



Active ingredients:

Cefotaxime Sodium - 1000 mg.



Excipients:

None.

DOSAGE

Intramuscularly and intravenously.

For intramuscular injection, 500 mg of the drug is dissolved in 2 ml (respectively 1 g in 4 ml) of sterile water for injection or Lidocaine. Enter deep into the gluteal muscle. An intramuscular injection also uses a 1% Lidocaine solution (500 mg - 2 ml, 1000 mg - 4 ml) as a solvent.

For intravenous administration, 500-1000 mg of cefotaxime is dissolved in 10 ml of sterile water for injection. Enter slowly for 3-5 minutes.

For drip administration (within 50-60 minutes) dissolve 2000 mg of the drug in 100 ml of isotonic sodium chloride solution or 5% glucose solution. The usual dose of cefotaxime for adults and children over 12 years of age is 1000 mg every 12 hours. In severe cases, the dose is increased to 3000 or 4000 mg per day, the drug is administered 3 or 4 times 1000 mg. Depending on the severity of the disease, the daily dose may be increased to a maximum of 12000 mg. The usual dose for newborns and children under 12 years old - 50-100 mg/kg body weight per day with intervals of administration from 6 to 12 hours. For premature infants, the daily dose should not exceed 50 mg/kg. In case of impaired renal function, the dose is reduced. With creatinine clearance of 10 ml/min or less, the daily dose of the drug is halved.<

When determining glucose in urine by a non-enzymatic method (for example, the Benedict method), false-positive results are possible. With caution, appoint persons who drive vehicles and engage in activities that require increased concentration of attention and rapid motor reaction.

SIDE EFFECTS AND PRECAUTIONS

Overdose Symptoms: convulsions, encephalopathy (in the case of large doses, especially in patients with renal failure), tremors, increased neuromuscular irritability. Treatment: symptomatic therapy.

Allergic reactions: urticaria, chills or fever, rash, itching, swelling of the face, laryngeal edema, bronchospasm, eosinophilia, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), bullous rash.

From the digestive system: nausea, vomiting, diarrhea or constipation, flatulence, abdominal pain, impaired liver function (increased activity of "liver" transaminases, alkaline phosphatase, hepatitis, jaundice, blood in the feces, hypercreatininemia, hyperbilirubinemia), stomatitis, glossitis, pseudomembranous colitis.

From the hemopoietic organs: leukopenia, neutropenia, granulocytopenia, thrombocytopenia, hemolytic anemia, hypocoagulation, agranulocytosis. From the urinary system: impaired renal function (azotemia, increased urea in the blood, oliguria, anuria, interstitial nephritis), hypercreatinemia.

From the nervous system: headache, dizziness, fainting, cramps, fatigue, encephalopathy (when prescribed in high doses), motor disorders, weakness.

From the cardiovascular system: lowering blood pressure, potentially life-threatening arrhythmias after rapid bolus injection into the central vein.

Laboratory indicators: false positive Coombs test.

Local reactions: inflammatory reaction at the injection site, including phlebitis and thrombophlebitis, soreness along the vein, soreness and infiltration at the site of intramuscular injection, redness of the skin.

Other: superinfection (in particular, candidal vaginitis), excessive growth of cefotaxime-resistant organisms. In the treatment of borreliosis: the Yarish-Herksheimer reaction (during the first days of treatment), skin rash, itching, fever, leukopenia, increased activity of liver transaminases, shortness of breath and discomfort in the joints.

STORAGE

Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.

QUESTIONS?

Ask us any questions about CEFOTAXIME.